Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE Our results suggest that CYP2D6 ultra-rapid metabolizer status contributes to venlafaxine-XR treatment remission in MDD patients; in particular, there is a PK-PD interaction with treatment remission associated with CYP2D6 URM phenotype and SLC6A4 5-HTTLPR L/L or SLC6A2 G1287A G/A genotype, respectively. 30578947 2019
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE CYP-GUIDES (Cytochrome Psychotropic Genotyping Under Investigation for Decision Support) is a randomized controlled trial (RCT) comparing 2 outcomes in hospitalized patients with major depressive disorder (MDD) treated according to the patient's CYP2D6 genotype and functional status versus standard psychotropic therapy. 31838256 2019
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease BEFREE Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. 29327975 2018
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis. 27187662 2016
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease GWASCAT Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. 24528284 2014
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease PSYGENET 47 patients with Major Depressive Disorder, treated with V 75 - 300 mg/day, underwent CYP2D6 genotyping using the INFINITI-CYP2D6 assay. 24660534 2014
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene. 23734807 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease PSYGENET A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene. 23734807 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease PSYGENET The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder. 24014145 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. 23081704 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease PSYGENET The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. 23081704 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder. 24014145 2013
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. 21861666 2011
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease PSYGENET CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. 21861666 2011
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE The risk of major depression in CYP2D6*4/*4 was not significantly different from extensive metabolizers (OR = 0.85; 95% CI: 0.36-2.00; p = 0.72). 19374513 2009
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 GeneticVariation disease BEFREE This paper explores the link between CYP2D6 genotype and antidepressant-associated ADRs in outpatients being treated for major depression with either nortriptyline or fluoxetine. 14716707 2004
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.400 Biomarker disease BEFREE Both poor and ultrarapid CYP2D6 metabolizers of tamoxifen have a worse prognosis for breast cancer compared with normal metabolizers after receiving a standard dose of tamoxifen. 31800347 2020
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.400 Biomarker disease BEFREE From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer. 31559573 2020
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.400 Biomarker disease BEFREE <b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer. 31769341 2020
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.400 Biomarker disease BEFREE The aim of this study was to determine the effectiveness of CYP2D6 pharmacogenetic screening to accelerate drug dosing in older patients with depression initiating nortriptyline or venlafaxine. 31688392 2020
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.400 Biomarker disease BEFREE 182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes. 31120287 2020
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.400 Biomarker disease BEFREE The aim of this study was to determine the effectiveness of CYP2D6 pharmacogenetic screening to accelerate drug dosing in older patients with depression initiating nortriptyline or venlafaxine. 31688392 2020
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.400 Biomarker disease BEFREE 182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes. 31120287 2020
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.400 Biomarker disease BEFREE Both poor and ultrarapid CYP2D6 metabolizers of tamoxifen have a worse prognosis for breast cancer compared with normal metabolizers after receiving a standard dose of tamoxifen. 31800347 2020
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.400 Biomarker disease BEFREE From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer. 31559573 2020